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Abstract 
BACKGROUND: There has been a few studies about the predictability of metabolic syndrome 
(MetS) based on the Framingham risk score (FRS) as a tool for predicting the risk of 10-years 
cardiovascular diseases (CVD) in Iranian population. The aim of this study was to compare the 
risk stratification obtained with the FRS and MetS in a cohort of the Iranian population. 
METHODS: In this population-based study Kerman Coronary Artery Disease Risk study, Iran, MetS 
was diagnosed as defined by the revised National Cholesterol Education Program definition criteria 
(ATPIII) and the FRS was calculated using a computer program, previously reported algorithm. 
RESULTS: Overall, the prevalence 10-years risk of CVD for patients with MetS was significantly 
different with those without MetS (74.3 vs. 86.4% for low-risk patients, 18.1 vs. 12.3% for 
intermediate-risk people, and 7.6 vs. 1.3% for high-risk individuals) (P < 0.001). The frequency 
of intermediate-risk and high-risk for 10-year CVD in men with MetS (39.5 and 18.3%, 
respectively) was considerably higher than women with MetS (3.2 and 0.1%, respectively). Using 
multiple logistic regression, the odds ratio of MetS in intermediate-risk and high-risk FRS group 
was 1.7 and 6.7, respectively (P < 0.001). 
CONCLUSION: Significant association between the presence of MetS and high risk for CVD 
based on FRS was revealed in both men and women indicating a good concordance between 
MetS and FRS in predicting the risk of CVDs. However, the odds ratio of the development of risk 
of cardiovascular events among women was higher than men with MetS. 
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Introduction 
The Framingham risk score (FRS) is a simplified 
and common clinical tool for assessment of the risk 
level of coronary artery disease (CAD) as well as for 
identifying individuals who were candidate for risk 
factors modification.1 This tool consists of various 
coronary risk components including gender, age, 
smoking, systolic blood pressure, and lipid profile 
state. FRS is the most applicable method for 
predicting a person’s chance of developing 
cardiovascular disease (CVD) in long-term.2,3 
Because this risk score give an indication of the 
likely benefits of prevention, it can be effectively 
useful for both the patient and for the clinicians in 
deciding whether lifestyle modification and 
preventive medical treatment,4,5 and for patient 
education, by identifying men and women at 
increased risk for future cardiovascular events.6 
However, despite the applicability of this tool, it is 
powerless to evaluate some key factors, which 
influenced by dietary and metabolic patterns 
modification. Proverbially, it remained unknown 
whether the FRS is a good predictor of metabolic 
disturbances underlying ischemic heart disease.7 
Moreover, the FRS has been shown to overestimate 
coronary disease risk in Europeans and thus its 
recalibration in special populations is 
recommended.8 
Because of metabolic syndrome (MetS) defined 
as a complete cluster of cardiovascular metabolic 
risk factors even diabetes mellitus, insulin resistance, 
and abdominal obesity, it may offer a better view of 
the prediction of coronary heart disease in 
suspected individuals.7,9-11 However, findings of 
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previous studies on comparing the predictive value 
of FRS versus MetS have been varied widely. 
Although the MetS score with age included has 
been identified to be a valid tool for predicting 
CVD and its predictive ability was as good as the 
FRS,12 some others have emphasized inferiority of 
MetS toward the FRS.13-16 
There has been no study about the predictability 
of MetS according to FRS in Iranian population. 
The aim of this study was to compare the risk 
stratification obtained with the FRS between 
individuals with and without MetS in a cohort of 
the Iranian population. 
Materials and Methods 
This population-based study is a great part of The 
Kerman, Iran, CAD Risk study that scheduled for a 
cohort of 5874 individuals aged 15-75 years and 
residence in Kerman city addressing the information 
of the risk profile of CAD including serum lipids, 
physical activity, alcohol and drugs addiction, 
mental disorders like stress and depression, 
hypertension as well as dietary regimens. The study 
was approved by the research and ethics 
committees of the Kerman University of Medical 
Sciences, Iran, and informed consent was obtained 
from all participants.  
In this survey, a detailed interview regarding 
social demographics and risk profile was 
administered and all subjects underwent a clinical 
examination that included measurement of body 
composition, systolic and diastolic blood 
pressure, serum blood sugar and serum lipids. We 
examined weight and standing height expressed as 
a body mass index (weight in kilograms divided 
by height in meters squared). The waist 
circumference (WC) was measured in a horizontal 
plane, midway between the inferior margin of the 
ribs and the superior border of the iliac crest. 
Blood pressure was recorded using an automatic 
oscillometric blood pressure recorder after at 
least 5 min of rest in a chair and arm supported at 
heart level. Systolic blood pressure was measured 
at the point where the first of two or more 
sounds was heard (Phase 1), and diastolic blood 
pressure before the disappearance of sounds 
(Phase 5). For biochemical analysis, blood 
samples of 5 ml were drawn after 12 h overnight 
fasting for measuring lipid profile, fasting blood 
sugar, and hemoglobin A1c. Plasma glucose was 
measured using the glucose oxidase-peroxidase 
method. The level of serum lipid profile was also 
determined by standard enzymatic procedures.  
MetS was diagnosed as three or more of the 
following five factors as defined by the revised 
National Cholesterol Education Program  definition 
criteria for Asian population: (1) fasting triglycerides > 
150 mg/dl or lipid medications; (2) systolic blood 
pressure > 130 mmHg, diastolic blood pressure > 85 
mmHg, or antihypertensive medications; (3) fasting 
plasma glucose > 5.6 g/dl or diabetes medications; (4) 
high-density lipoprotein (HDL) cholesterol < 40 
mg/dl (men) or < 50 mg/dl (women); and (5) WC > 
102 cm (men) or > 88 cm (women).17 
The FRS was calculated using a computer 
program18 and based on using a previously reported 
algorithm,2 which takes into account age, sex, total 
cholesterol, HDL cholesterol, systolic and diastolic 
blood pressure, smoking and the presence of 
diabetes. The participants were then classified into 
groups according to cardiovascular risk consistent 
with the obtained score that individuals with low 
risk had 10% or less coronary disease risk at 10 
years, with intermediate-risk 10-20%, and with high 
risk 20% or more.19 
Results were presented as mean ± standard 
deviation for quantitative variables and were 
summarized by absolute frequencies and percentages 
for categorical variables. Categorical variables were 
compared using chi-square test or Fisher’s exact test 
when more than 20% of cells with expected count of 
< 5 were observed. Quantitative variables were also 
compared using t-test. Statistical significance was 
determined as a P < 0.050. All statistical analysis was 
performed using SPSS software for Windows (version 
20, SPSS Inc., Chicago, IL, USA). 
Results 
The mean age for the entire cohort was  
44.34 ± 16.32 years (range 10.87 years). Among, 
MetS was diagnosed in 2346 subjects (39.7%). The 
baseline demographics comparing subjects with and 
without MetS are shown in table 1. Compared to non-
MetS group, those with MetS were older, were more 
female, had higher systolic and diastolic blood 
pressure, had higher fasting blood sugar, and also had 
different lipid profile status as higher serum total 
cholesterol, serum triglyceride, and lower HDL. 
Overall, 74.3% patients with MetS were low-risk, 
18.1% were intermediate-risk, and 7.6% were high-
risk for 10-year CVD. Besides, the  
10-year risk for cardiovascular disorders according 
to FRS scoring was significantly lower in those 
without MetS that 86.4% were low-risk, 12.3% were 
intermediate-risk, and only 1.3% of them were high-
risk for cardiovascular disorders (Table 2). This 
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significant association between the presence of 
MetS and high risk for CVD based on FRS was 
revealed in both men and women indicating a good 
concordance between MetS and FRS in predicting 
the risk of CVD s. However, the prevalence 
intermediate- and high-risk for 10-years risk of 
CVD in men (39.5 and 18.3%, respectively) was 
significantly much more compared with those in 
women (3.2 and 0.1%, respectively) (P < 0.001) 
(Table 2). In other words, the frequency of low-risk 
category in women was significantly high than men 
(96.8 vs. 42.1%, respectively). 
As shown in table 3, using multiple logistic 
regression modeling and considering low-risk group as 
the reference, the odds ratio of risk for MetS was 1.7 
in intermediate-risk FRS group and was 6.7 in high-
risk FRS group (P < 0.001). The odds ratios of 
intermediate-risk and high-risk among men 
respectively were 2.63 and 11.4 (P < 0.001) and among 
women were 12.02 and 22.01 (P < 0.001). The 10-year 
increased risk for CVDs according to FRS risk 
categories was significantly associated with the number 
of MetS definitional components (Figure 1) that  
10-year high risk of cardiovascular disorders was 
predict in 0.6% of patients with one MetS component, 
2.6% in two MetS components group, 7.1% in three 
MetS components group, 8% in individuals with four 
or five components group (P < 0.050). 
Discussion 
Our study performed on a great sample of the 
Iranian population revealed a prevalence of 39.7% 
for MetS that is nearly consistent with the previous 
reports. In a recent report, the overall prevalence of 
MetS in different Iran areas ranged between 30% 
and 45%20-23 that is nearly in the range that reported 
in neighbor country of Iran including Saudi 
(39.3%)24 and Turkish (33%) populations.25 
However, the global prevalence of this 
phenomenon varies widely so that the published 
reports from western countries and from 
southeastern nations documented MetS prevalence 
of 24.0 and 14.2%, respectively.26,27 The observed 
discrepancy might be due to the different in used 
MetS definitional criteria and also to the differences 
in genetic predisposition, various lifestyle patterns 
as well as different nutritional behaviors leading 
variance in the prevalence of MetS for different 
communities and ethnic groups. 
 
Table 1. Baseline characteristics in individuals with and without metabolic syndrome (MetS) 
Characteristics Group with MetS (n = 2346) Group without MetS (n = 3528) P  
Female gender (%) 1392 (58.9) 1846 (52.2) 
< 0.001 
Age (year) 53.14 ± 13.16 38.48 ± 15.57 
Systolic blood pressure (mmHg) 128.85 ± 20.40 109.97 ± 20.14 
Diastolic blood pressure (mmHg) 82.07 ± 10.54 74.22 ± 9.01 
WC (cm) 93.06 ± 10.99 79.61 ± 10.90 
Fasting blood sugar (mg/dl) 121.59 ± 48.96 91.23 ± 22.53 
Serum triglyceride (mg/dl) 198.43 ± 113.34 113.07 ± 75.35 
Serum total cholesterol (mg/dl) 208.47 ± 45.73 181.84 ± 40.50 
Serum HDL (mg/dl) 35.01 ± 8.54 40.58 ± 10.91 
MetS: Metabolic syndrome; WC: Waist circumference; HDL: High-density lipoprotein 
 
Table 2. The comparison of 10-year risk for cardiovascular disorders [according to Framingham risk score (FRS) scoring] 
between two groups of with and without MetS (results reported for the whole population and gender subgroups) 
Characteristics Group with MetS (n = 2346) Group without MetS (n = 3528) P 
Total   
< 0.001 
Low-risk 1756 (74.3) 3056 (86.4) 
Intermediate-risk 428 (18.1) 435 (12.3) 
High-risk 179 (7.6) 46 (1.3) 
Men   
Low-risk 409 (42.1) 1215 (71.9) 
Intermediate-risk 384 (39.5) 430 (25.4) 
High-risk 178 (18.3) 46 (2.7) 
Women   
Low-risk 1347 (96.8) 1841 (99.7) 
Intermediate-risk 44 (3.2) 5 (0.3) 
High-risk 1 (0.1) 0 (0.0) 
MetS: Metabolic syndrome 
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Table 3. Multiple logistic regression models for assessing the odds ratio of metabolic syndrome (MetS) in the 
levels of Framingham risk score (FRS) risk scores 
FRS risk categories Odds ratio 95% CI P 
Total    
Low-risk (ref) 1 - - 
Intermediate-risk 1.712 1.480-1.981 
< 0.001 High-risk 6.772 4.872-9.413 
Men    
Low-risk (ref) 1 - - 
Intermediate-risk 2.653 2.222-3.168 
< 0.001 High-risk 11.495 8.157-16.199 
Women    
Low-risk (ref) 1 - - 
Intermediate-risk 12.027 4.757-30.412 
< 0.001 High-risk 22.009 10.151-46.790 
CI: Confidence interval; FRS: Framingham risk score 
 
 
Figure 1. Association between Framingham risk score risk categories and number of metabolic syndrome components 
 
Several studies have been conducted in past to 
assess the relative merits of MetS and FRS for 
prediction of cardiovascular risk, but have shown 
inconsistent results.9,13,16 Furthermore, numerous 
studies attempted to evaluate the concordance 
between these two predicting tools confirming the 
superiority of one method over the other. Our study 
showed a strong correlation between these tools so 
that higher-risk FRS status has been expressed to be 
associated with the presence of MetS and its 
numbers of components. On the other hand, both 
MetS and FRS can be effectively used for predicting 
the long-term appearance of cardiovascular events. 
However because of some potential limitations of 
FRS such as heavy dependent on age factor and 
underestimation of cardiovascular disorders in the 
young,28,29 and lack of coverage several prominent 
features of MetS such as obesity, hyper-
triglyceridemia and elevated high sensitivity-C 
reactive protein levels,17 the use of MetS is more 
preferred to predict occurrence of CVDs. Yu et al. 
showed that MetS score, including age appeared 
greater association with CVD than FRS on the same 
exposed subjects and thus can have more validation 
than FRS and, therefore, its predictive ability can be 
higher than the latter tool.12 In contrast, because of 
short-term modification of some life-style-related 
risk factors such as blood sugar state or obesity, 
MetS may be an independent determinant of 
significant CAD only among those individuals at 
low 10-year risk for future coronary events.30 
Moreover, MetS was found to be less effective at 
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predicting heart disease than the FRS according the 
two recent US reports showing the syndrome to be 
less predictive of CVD then the FRS.13,14 
Meanwhile, the combined use of these two tools did 
not result in more benefits. In the recent report of 
the National Heart, Lung, and Blood Institute and 
American Heart Association conference 
proceedings, analysis of the Framingham data 
indicated that no advantage is gained in risk 
assessment by adding the components of MetS to 
the FRS.9 Thus, it still remains to be determined 
whether FRS or MetS is a better risk assessment 
tool in young individuals. 
This study had some potential limitations. First, 
its cross-sectional nature and the lack of patients 
with the angiographically established CVD did not 
allow us to evaluate whether MetS is a better marker 
of cardiovascular risk than FRS in our individuals. It 
was preferred to assess this concordance 
considering both CVD and healthy subgroups. In 
addition, our study only covered a local population 
in eastern Iran and did not include a great sample 
from all regions of the country. Therefore, results 
are not generalized to all parts of the country. 
In the present study, we found that in spite of 
increasing frequency of moderate- and high-risk for 
10-year cardiovascular events in men, but the odds 
ratio of development of MetS among women in 
both moderate- and high-risk groups compared 
with low-risk group as reference group was 
remarkably higher in men. The present findings 
seem to be consistent with other research in the 
literature review, which found somehow the similar 
results. In a meta-analysis, patients with the MetS 
had approximately 60% increased risk of CVD than 
those without the MetS and that the MetS could be 
a stronger risk factor for CVD in women compared 
to men.31 In another study among a group of people 
with low prevalence of coronary heart disease 
(CHD), stroke, and diabetes, the probability to 
develop CHD after controlling other serious risk 
factors, among women with the MetsS (2 times) was 
greater than that in men (1.5 times).14 There have 
found an association between the MetS and an 
increased number of CVD events.32,33 The MetS 
worsens the development of some main non-
communicable diseases like diabetes, CAD, 
myocardial infarction, stroke, and heart failure. It 
has indicated that the MetS can be a stronger 
predictor of CVD events even than diabetes. The 
studies have shown the discrepancies between men 
and women concerning the role of the MetS on the 
development of diseases events. The MetS was 
related to an increased prevalence of coronary heart 
disease.34-37 In Marroquin et al.’s study, which 
conducted only in women, the MetS deteriorated 
the prognosis of CVD. The hazard ratio of the 
impact of the MetS on the prognosis of 
cardiovascular events was 4.93, almost 5 times 
higher than that in women without CAD, which 
was 1.41.38 There was a strong association between 
the MetS and CVD mortality among women 
compared with men (more than twice) based on the 
data from the San Antonio Heart Study.39 Dekker et 
al.40 also suggested that associations of MetS with 
non-fatal CVD generally were stronger in women 
than in men. Although the recent study concluded 
that the FRS can underestimate absolute coronary 
heart disease risk in older adults, especially among 
women by 51% compared to 8% in men.41 
Conclusion 
In conclusion, both MetS and FRS predicting tools 
can serve as simple clinical approaches to identifying 
cardiovascular vulnerable and at-risk patients in order 
to its acceptable concordance. However, because of 
covering some important metabolic components, 
including obesity, blood sugar changes as well as pro-
inflammatory status, the use of MetS for predicting 
CVDs is preferable. 
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